Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01831362
Other study ID # K23AT006328-01A1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2013
Est. completion date March 15, 2016

Study information

Verified date November 2018
Source Brown University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study addresses NCCAM's request for research that investigates the neuropsychological mechanisms underlying mind-body therapies, and for precise criteria and better delineation of meditation practices.

The purpose of this study is to assess the clinical efficacy and mechanism of action of 2 component practices of "mindfulness meditation", i.e. focused awareness (FA) and open monitoring (OM) in comparison to each other and to the standard package, Mindfulness-Based Cognitive Therapy (MBCT).


Description:

Meditation, particularly mindfulness meditation, is one of the most popular Complementary and Alternative Medicine (CAM) therapies for alleviating emotional stress, depression and anxiety. While standardized meditation-based treatment packages like Mindfulness Based Stress Reduction (MBSR) and Mindfulness-based Cognitive Therapy (MBCT) have reliably shown sustained improvements in emotional disturbances and wellbeing, they contain so many different components and practices that the active ingredient cannot be ascertained. What is commonly called "Mindfulness" meditation is actually comprised of two separate practices: 1) focused awareness practice (FA), and 2) open-monitoring practice (OM). This project aims to create separate 8 week programs for FA and OM meditations, compare their clinical efficacy and investigate their separate mechanisms of action in individuals with clinically significant levels of persistent negative affect and depression. The clinical benefit and mechanism of action of focused awareness (FA) vs open-monitoring (OM) vs MBCT will be examined with a 3-armed randomized control trial of these 8 week interventions. Outcome variables include negative affect (depression, anxiety, stress) and wellbeing. Hypothesized mediating processes include objectively measured attention, emotion regulation and the basic wakefulness on which they depend.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date March 15, 2016
Est. primary completion date March 15, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- English-speaking

- ages 18-65

- mild-severe levels of depression or high level of negative affect

Exclusion Criteria:

- Current:

- age <18 or >65

- inability to read and write in English

- Extremely severe levels of depression

- active suicidal ideation

- presence of Axis I personality disorder

- panic disorder

- post-traumatic stress disorder

- obsessive-compulsive disorder

- eating disorder, or substance abuse/dependence

- current psychotherapy

- change in antidepressant medication type or dosage in the last 8 weeks.

Lifetime history exclusions:

- bipolar disorder

- psychotic disorders

- persistent antisocial behavior or repeated self-harm,

- borderline personality disorder,

- organic brain damage

- regular meditation practice

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindfulness-Based Cognitive Therapy

Focused Attention (FA)

Open- Monitoring


Locations

Country Name City State
United States Brown University Clinical and Affective Neuroscience Laboratory Providence Rhode Island

Sponsors (1)

Lead Sponsor Collaborator
Brown University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Five Facet Mindfulness Questionnaire (FFMQ) 39-item self-report questionnaire of mindfulness skill acquisition (attention, non-reactivity) baseline, week 3,5,7,8,20
Other Self-Compassion Scale (Neff 2003) 26-item self report of attitudes towards oneself baseline, 8 weeks, 20 weeks
Other Positive and Negative Affect Scale (PANAS) 60-item self report of emotional states week 1,2,3,4,5,6,7,8
Primary Change in Inventory of Depressive Symptomatology 30-item clinician administered interview about unipolar depression symptoms baseline, 8 weeks, 20 weeks
Primary change in Depression, Anxiety Stress Scale (DASS) 42-item self-report questionnaire on depression, anxiety and stress symptoms baseline, week 2,4,6,8, 20
Primary change in Wellbeing Scale (WBS) 73-item self-report questionnaire of psychological wellbeing baseline, 8 weeks, 20 weeks
Secondary Change in alpha-theta EEG power from baseline to 8 weeks Resting/spontaneous EEG power in 5-9 Hz range baseline and 8 weeks
Secondary Change in Facial EMG power from baseline to 8 weeks Facial EMG response to emotional (IAPS) photos (reactivity + regulation) baseline and 8 weeks
Secondary Sustained Attention to response Task (SART) 40 minuted sustained attention, go-no-go task baseline, 8 weeks
Secondary Difficulties in Emotion Regulation Scale (DERS) 36-item self report of emotion regulation baseline, 8 weeks, 20 weeks
Secondary Attention Control Questionnaire (Derryberry & Reed, 2002) 20-item self report measure of attentional abilities baseline, 8 weeks, 20 weeks